

## West Virginia Clinical Translational Science Institute (WVCTSI) Tracking and Evaluation Quarterly Report

1<sup>st</sup> Quarter of Fiscal Year 2018-2019

Reporting Period: July 1, 2018 – Sept. 30, 2018



CAMC / WVU Charleston



Marshall University



West Virginia School of  
Osteopathic Medicine



WV Veterans Affairs




National Institute for  
Occupational Safety and  
Health



West Virginia  
University



WVU Medicine



Report Prepared by:

Reagan Curtis, Taylor Mikalik, David Loomis, Abhik Roy, and Malayna Bernstein

**West Virginia Clinical Translational Science Institute**  
**Tracking and Evaluation Quarterly Report**  
(July 1, 2018 – Sept. 30, 2018)

**Contents**

Executive Summary.....	3
Quarterly Reporting Annual Timeline Targets .....	4
Administrative Core .....	5
<i>Figure 1. Contributions per core to WVCTSI linked publications.</i> .....	5
<i>Figure 2. External funding proposals amount and category per core.</i> .....	6
<i>Figure 3. External funding awards dollar amount per core.</i> .....	6
Clinical Research Design, Epidemiology & Biostatistics Core .....	7
<i>Figure 4. CRDEB iLab Core Management System services logged by month and service type.</i> .....	7
Clinical Research Resources & Facilities Core .....	8
Community Engagement & Outreach Core .....	9
<i>Figure 5. CEO iLab Core Management System services logged by month and service type.</i> .....	9
Pilot Projects Core.....	10
Professional Development Core .....	11
<i>Figure 6. Investigator development services per service category as logged in iLab.</i> .....	11
Technology and Resources for Core Laboratories .....	12
Tracking and Evaluation Core .....	13
Marshall University .....	14
Charleston Area Medical Center (CAMC).....	15
West Virginia School of Osteopathic Medicine (WVSOM) .....	16

### Executive Summary

This is the quarterly tracking and evaluation report of the WV Clinical and Translational Science Institute (WVCTSI) for the 1st quarter (Q1) of fiscal year 2018/2019 (Y7), which covers a reporting period from July 1, 2018 through September 30, 2018. The WVCTSI received verbal approval for year 7 renewal funding dated July 23, 2018 with an annual award of \$4,000,000 for the budget period from July 1, 2018 through June 30, 2019 and a total project period from August 15, 2012 through June 30, 2022.

This report was prepared by the Tracking and Evaluation Core and is organized by specific aim within each key component area/core plus information from partner institutions, Charleston Area Medical Center, Marshall University, and WV School of Osteopathic Medicine. This report does not describe every tracking and evaluation metric in each core, rather key elements and recommendations are summarized and readers are referred to the Quarterly Data Sheet (Excel) distributed with this report for information on all metrics for all cores and partners included.

There were 48 peer-reviewed publications linked to WVCTSI funding, 45 external funding proposals, and 58 funded awards this quarter. These numbers demonstrate consistent productivity and return on investment related to external funding, especially in the context of over \$17 million in external funding awards this quarter. However, there has been a decline in linked publications (Y6Q3=80, Y6Q4=62) that will be increasingly concerning if it continues. Other notable accomplishments include:

- 228 iLab users requested 554 services. 72 services were for proposal development and 12 WVCTSI members received external grant proposal development, editing, and writing services;
- CRDEB completed 11 IDR projects, added 67 new REDCap users, and serviced 6 new TriNetX data set requests, 99 new BMIR-related inquiries, and 37 new statistical consultations while contributing to 16 linked publications and \$2 million in externally funded awards;
- The Clinical Trials Center of Excellence provided regulatory (29), study coordination (14), quality assurance (3), and accounting assistance (23) for non-WVCTSI clinical studies.
- CEO reported 5 new Project ECHO sites and 3 new partner organizations, while contributing to 1 funded award (\$300k) and 3 linked publications;
- The Pilot Core contributed to over \$15 million in external funding proposals, almost \$1 million in external funding awards, and 7 linked publications while funding 2 new and 21 ongoing pilots;
- There were 23 internal (10 new) and 8 external (all new) active Scientific and Career Success (SACS) program members. The PD Core contributed to almost \$2 million in external funding proposals, over \$2 million in external funding awards, and 13 linked publications;
- TRCL contributed over \$1.3 million in external funding awards and 1 linked publication. 350 samples were collected (138 Marshall, 212 WVU) and 92 utilized from the biospecimen repository. There were 7 (4 Marshall, 3WVU) Illumina genomics and 9 MicroCT projects;
- WVCTSI-related activity at Charleston Area Medical Center, WV School of Osteopathic Medicine, and Marshall University continues to increase. There were 4 linked publications, 2 external funding proposals, and 4 externally funded awards reported by partners this quarter.

Overall recommendations from Tracking and Evaluation Core include the following:

- Increase efforts to support peer-reviewed publication by WVCTSI-supported project personnel;
- Ensure partner activity at NIOSH and Veterans Affairs is appropriately integrated and reported;
- Identify year 7 annual targets for all appropriate metrics for cores and partners;
- Ensure transparent and consistent utilization of iLab across cores and partners;
- Continue to increase partner engagement outside of Morgantown; and
- Maintain focus on priority health areas when allocating resources and effort.

### Quarterly Reporting Annual Timeline Targets

#### 1<sup>st</sup> quarter Reporting Period = July 1 – Sept 30

Sept 18	1 <sup>st</sup> quarter report task assigned to each KCA/Partner via email to key contacts
Oct 1	TEC begins data acquisition from repositories (e.g., iLab)
Oct 7	Quarterly data submission due from key contacts to TEC
Sept-Oct	Pre/post submission meetings (TEC and key contacts)
Oct 28	1 <sup>st</sup> quarter formative evaluation report and metric data distributed by TEC
Nov-Dec	Steering Committee discusses 1 <sup>st</sup> quarter formative evaluation

#### 2<sup>nd</sup> quarter Reporting Period = Oct 1 – Dec 31

Dec 18	2 <sup>nd</sup> quarter report task assigned to each KCA/Partner via email to key contacts
Jan 1	TEC begins data acquisition from repositories (e.g., iLab)
Jan 7	Quarterly data submission due from key contacts to TEC
Dec-Jan	Pre/post submission meetings (TEC and key contacts)
Jan 28	2 <sup>nd</sup> quarter formative evaluation report and metric data distributed by TEC
Feb-Mar	Steering Committee discusses 2 <sup>nd</sup> quarter formative evaluation

#### 3<sup>rd</sup> quarter Reporting Period = Jan 1 - Mar 31

Mar 18	3 <sup>rd</sup> quarter report task assigned to each KCA/Partner via email to key contacts
Apr 1	TEC begins data acquisition from repositories (e.g., iLab)
Apr 7	Quarterly data submission due from key contacts to TEC
Mar-Apr	Pre/post submission meetings (TEC and key contacts)
Apr 28	3 <sup>rd</sup> quarter formative evaluation report and metric data distributed by TEC
May-June	Steering Committee discusses 3 <sup>rd</sup> quarter formative evaluation

#### 4<sup>th</sup> quarter Reporting Period = Apr 1 – June 30

June 18	4 <sup>th</sup> quarter report task assigned to each KCA/Partner via email to key contacts
July 1	TEC begins data acquisition from repositories (e.g., iLab)
July 7	Quarterly report data due to TEC from each core
June-July	Pre/post submission meetings (TEC and key contacts)
July 28	4 <sup>th</sup> quarter formative evaluation report and metric data distributed by TEC
Aug-Sept	Steering Committee discusses 4 <sup>th</sup> quarter formative evaluation


## Administrative Core

**Specific Aim 1. Implement an effective operational structure that facilitates attainment of all proposed WVCTSI Specific Aims and projects.**

WVCTSI researchers reported 7 presentations, 48 linked publications, 45 external funding proposals, and 58 externally funded awards totaling over \$17,000,000 in awards for Q1. The number of WVCTSI staff remained at 33. Core contributions to publications are visualized in Figure 1. Figures 2 and 3 display core contributions to external funding proposals and awards.



## Publications by Core or Institution



The iLab Core Management System was launched during Y6 Q2 to streamline service delivery across WVCTSI. The number of iLab users increased from 326 (Y6 Q4) to 435 (Y7 Q1). 72 proposal development services were provided to a total of 12 members: 66 were provided to WVU, 5 to Marshall University, and 1 to other affiliates. 11 WVCTSI members participated in grant writing groups.

**Figure 1. Contributions per core to WVCTSI linked publications.**

**Specific Aim 2. Create policies and procedures to drive performance, transparency, constructive communication and collaboration among multiple, diverse stakeholders (i.e., investigators, rural providers, community members).**

WVCTSI added 120 new members this quarter (total = 2094). WVCTSI website traffic increased by 88.3 average hits per day during this quarter (total average hits for Q1 = 323.3). WVCTSI's social media engagement also increased: Facebook (+3 likes), Twitter (+13 followers), and Listserv (+104 subscribers).

**Specific Aim 3. Provide sound fiscal and resource management, ensuring appropriate resourcing of cores, flexibility to meet changing needs and environments, and sustainability of services.**

Securing external funding is vital to fiscal management of WVCTSI resources. WVCTSI provided support to 45 external funding proposals and 58 external awards were funded this quarter (see Figures 2 and 3). The percentage of NIH award expended was 9% overall for this quarter and varied across core from 26% (CRRF) to 2% (TEC). No cost transfers or corrections to ensure accounting standards were reported for this quarter.


**Specific Aim 4. Recruit talented, committed investigators addressing research questions relevant to the WVCTSI priority health areas.**

No new investigators recruited this quarter.


### Administrative Core

#### Key Recommendations

- Increase service utilization across partners.
- Work with TEC to determine whether presentations should be an annual rather than quarterly metric.
- Ensure appropriate utilization of funds to reach annual target of 100% with consistency across cores.
- Clarify which, if any, proposal development services should remain in Administration Core.
- Set year 7 annual targets for all appropriate metrics.



**Figure 2. External funding proposals amount and category per core.**




**Figure 3. External funding awards dollar amount per core.**


### Clinical Research Design, Epidemiology & Biostatistics Core

#### Specific Aim 1. Effectively engage investigators throughout WV by providing traditional services in biostatistics and epidemiology.

Investigators are actively engaged through the CRDEB core utilizing available resources including the Integrated Data Repository (IDR), REDCap, and TriNetX. There were 67 new REDCap users in Q1, with a total of 1,460, of which there were 1,010 from WVU, 12 from CAMC, and 8 from WVSOM. There were 225 ongoing REDCap projects reported. The total number of TriNetX users was 306, and there were 446 new TriNetX inquiries. There were 19 new data analysis or data management consultations and 12 sample size or power consultations in Q1.



### By the Numbers: Clinical Research Design, Epidemiology and Biostatistics Core Services



**Figure 4. CRDEB iLab Core Management System services logged by month and service type.**

#### Specific Aim 2. Implement cutting-edge tools and methods in biostatistics and epidemiology, with a particular focus on the needs of WV researchers.

The CRDEB core reported 99 BMIR-related inquiries. There was 1 new study design consultation and 13 other consultations. There was 1 new clinical design project consultation, 0 predictive modeling consultations, and 1 new epidemiology consultation.

#### Clinical Research Design, Epidemiology, & Biostatistics

##### Key Recommendations

- Continue to increase utilization at partner sites.
- Clarify efforts targeting specific aims 3 and 4.
- Help TEC connect iLab field labels to specific core metrics.
- Identify year 7 annual targets for all appropriate metrics.



**Specific Aim 3. Disseminate current and classical information in biostatistics and epidemiology.**

CRDEB contributed to 16 linked publications, almost \$2 million in external funding proposals, over \$2 million in funded awards, and 2 presentations, as well as reporting 3 consultations for manuscript preparation. However, the degree to which these efforts target this specific aim is unclear.

**Specific Aim 4<sup>1</sup>. Leverage the newly enhanced Integrated Data Repository (IDR2) and partnership through the Appalachian Research Consortium (ARC) to facilitate outcomes research, predictive modeling, and geospatial analysis.**

In Q1, there were 22 entries for IDR related to 17 unique users and 11 IDR projects reported as complete. No ARC information was reported.

**Clinical Research Resources & Facilities Core****Specific Aim 1. Create a Clinical Trials Center of Excellence (CTCOE) with connection to rural communities and practitioners, thereby providing access to cutting-edge trials addressing health disparities affecting West Virginians.**

CRRF contributed to roughly \$1 million of external funding proposals, predominately from State and Other sources, and over \$600k in external funding awards. There were 2 Early Stage PI's with industry or investigator-initiated funding. With an annual target accrual across studies of 1445, 180 total subjects enrolled in Q1.

The CTCOE provided regulatory (29), study coordination (14), quality assurance (3), and accounting assistance (23) for non-WVCTSI clinical studies. 2 quality audits were completed. TriNetX offered 10 studies to WVU this quarter, with 7 being accepted by WVU researchers, and 2 being activated. Total program income from service provision was not reported.

**Specific Aim 2. Establish the Environmental Exposures Unit to stimulate environmental health research in collaboration with the National Institute for Occupational Safety and Health (NIOSH).**

There were no data provided this quarter related to the Environmental Exposures Unit.

Clinical Research Resources & Facilities Key Recommendations
<ul style="list-style-type: none"> <li>• Clarify tracking and evaluation information needs relative to Specific Aim 2.</li> <li>• Identify year 7 annual targets for all appropriate metrics that are not equal to Q1 activity.</li> </ul>



<sup>1</sup> CRDEB Specific Aim 4 was previously CRRF Specific Aim 2. This revision was specified by letter to NIH dated November 27, 2017 and subsequently approved.




## Community Engagement & Outreach Core

### Specific Aim 1. Actively engage patients and other community stakeholders as research partners.

The WVPBRN reported 86 sites in Q1 and an intention to grow to 90 sites this year. There were 67 ECHO sites (annual target 72) with 5 of those new ECHO sites this quarter: Penn State, Allay Homecare, Alliance for Substance Abuse Progress at Bartholomew County, HRSA, and Columbia University Medical Center. Three additional partner organizations came on board: Phil Saul (CEO partnership with Children's Hospital), John Campo (WVPBRN and substance-use prevention research with youth), and Weimin Gao (CEO and WVPBRN). In Q1, there were 9 investigators mentored, 1 researcher connected to providers and lay partners, and 3 new creations of partnerships and organizations reported. There were 27 services provided for patient and community engagement, and 147 services provided for project development and success. Figure 5 visualizes CEO services and outcomes logged in



### By the Numbers: Community Engagement Core



iLab for Q1.

**Figure 5. CEO iLab Core Management System services logged by month and service type.**

During the first quarter, there were 8 networking opportunities described and planned focus group sessions were all completed prior to this reporting period. Community Advisory Board meetings and BOTG training sessions are planned for subsequent evaluation periods this year. 3 internal policy or practice changes were reported.

#### Community Engagement & Outreach

##### Key Recommendations

- Disaggregate and provide narrative for internal policy and practice changes.

**Specific Aim 2. Transform community-identified research questions into externally-funded projects that improve health outcomes in WVCTSI health priority areas.**

There were 8 new and 27 ongoing WVPBRN projects in Q1. Services provided for project development and success increased to 147, representing substantial progress toward an annual target of 200. However, it is not clear how these efforts directly relate to specific aim 2. The Community Advisory Board and BOTG Training are expected to more clearly relate to this specific aim when accomplished.


**Specific Aim 3. Translate and disseminate research results to inform West Virginia health policy and practice.**

In Q1 there were 5 services provided for Research Translation and Dissemination, as well as 4 funding opportunities identified. CEO contributed to 1 funded award (\$300k) and 3 linked publications.

**Pilot Projects Core**

**Specific Aim 1. Provide infrastructure supporting competitive pilot funding opportunities for early stage (ESI) and new investigators (NI) with subsequent mentored progression to project completion, publication, and external funding application.**

No applications or LOIs were due this quarter. 2 projects (1 Launch, 1 Collaborative) were awarded, including 1 ESI PI and 1 NIOSH PI. No workshops or trainings were provided. 18 services or consultations were provided including kick-off meetings for funded grants, budgetary consultations, and close-out meetings for grants coming to an end. Consultations occurred with WVU (17), MU (4), and WVSOM (1) collaborative partners. Mentoring of ESIs was not reported and new investigators were not reported as a separate category of those funded.



**Specific Aim 2. Advance collaborative research endeavors to address WVCTSI priority health areas within WV as well as throughout the Appalachian region.**

The Pilot Projects Core reported 21 ongoing projects that address critical health issues within WV including obesity, respiratory disease, cancer, and education and training related to opioid safety and response. The Pilot Core contributed to over \$15 million in external funding proposals, almost \$1 million in external funding awards, and 7 linked publications in Q1.

**Specific Aim 3. Implement the Launch Pad Pilot Program to maximize opportunities for commercialization of novel science.**


Funding was awarded to 1 Launch Pad pilot project this quarter.

Pilot Projects
Key Recommendations
<ul style="list-style-type: none"> <li>• Consider whether services to NIs and ESIs should be captured separately.</li> <li>• Increase participation in Launch Pad Pilots across partner sites.</li> <li>• Identify year 7 annual targets for all appropriate metrics.</li> </ul>

## Professional Development Core

**Specific Aim 1. Create the Scientific and Career Success (SACS) program to provide access to formal mentoring for C/T researchers of all career stages.**

### By the Numbers: Investigator Development Services



There were 23 internal (10 new) and 8 external (all new) active members in the SACS program in Q1. WVCTSI-supported scientists mentored 10 students in the INTRO program. Figure 6 displays year 7 quarter 1 Investigator Development Services per service category as logged in iLab, including mentoring for grant writing by pilot recipients as well as other clinical/translational investigators.



**Figure 6. Investigator development services per service category as logged in iLab.** Specific Aim 2. Develop formal programs that serve as “on-ramps” to introduce C/T research to early or new investigators and trainees at different career stages.

CTS Certificate shows that 2 applications were received, and 2 students were enrolled. WVU MS in CTS program had 17 students enrolled (9 new with 9 applications received). There were no new degrees conferred but 1 honor/award was noted. CTS PhD had 9 students enrolled (2 new). Education programming included 1 new academic course offered in Q1.

**Specific Aim 3. Develop educational opportunities to support and retain externally funded C/T researchers statewide.**

The Professional Development core contributed to almost \$2 million in external funding proposals, over \$2 million in external funding awards, and 13 linked publications. Education programming included 4 seminars with 90 unique participants (88 from WVU and 2 from WVSOM): (1) Clinical Trials Toolkit Series - How to Be Prepared for Your Next Audit: Regulatory Expectations, (2) Clinical Trials Toolkit Series: “Investigational Pharmacy: Improving Processes” and (3) “Set Up of Laboratory Testing: What Researchers Need to Know”, and (4) Update on Eating Disorders: Treatment and Research.

Professional Development
Key Recommendation
<ul style="list-style-type: none"> <li>Continue to work to increase participation across partner sites.</li> <li>Identify year 7 annual targets for all appropriate metrics.</li> </ul>

## Technology and Resources for Core Laboratories

The Technology and Resources for Core Laboratories core contributed over \$1.3 million in external funding awards and 1 linked publication. No external funding proposals were linked to this core.

**Specific Aim 1. To establish a statewide biospecimen repository that collects patient and study participant samples in WVCTSI priority health areas (addiction and resultant emerging epidemics, cancer, cardiovascular disease, and chronic lung disease).**

This was the second quarter in which samples were collected (the first collection began during Quarter 4 of the previous year), and this was the first quarter in which Marshall University (MU) has reported sample collection (138 by MU, 212 by WVU) and sample utilization (92 by MU, 0 by WVU). To date, no sample activity has been reported from CAMC. 30 WVCTSI-supported biospecimen projects were reported.

**Specific Aim 2. To establish a statewide West Virginia University (WVU) - Marshall University (MU) genomics shared research facility for the efficient generation of genomic and related data for C/T studies that address WVCTSI priority health areas.**


There was 1 Marshall WVCTSI study and 7 WVU genomics studies reported. There were 3 WVU Illumina projects and 4 at Marshall. Of the 14 runs reported this quarter, 4 were at WVU and 10 were at MU.

**Specific Aim 3. To establish a statewide WVU-MU shared Bioinformatics and Data Management (BDM) Facility for C/T studies that address WVCTSI priority health areas.**

4 bioinformatics educational sessions were provided with 120 participants from WVU and Marshall.

**Specific Aim 4. To establish state-of-the-art imaging in support of biologically relevant modeling of disease.**

8 WVCTSI investigators received imaging-related services. 9 educational sessions related to imaging were provided, with a total attendance of 8. 9 MicroCT and 3 MRI projects were reported. No clinical research projects were reported.



### Technology & Resources for Core Labs

#### Key Recommendations

- Identify year 7 annual targets for all appropriate metrics, in addition to those reported for MU.
- Consider opportunities to encourage clinical research projects and additional attendees at imaging educational sessions.

## Tracking and Evaluation Core

**Specific Aim 1. Develop Investigator Tracking and Support System (ITSS) utilizing quantitative and qualitative approaches to identify factors contributing to success or providing barriers to productivity.**

TEC personnel worked with key contacts across multiple cores to better understand how data entry is proceeding, data structure and architecture, data integrity, and data retrieval and reporting procedures and possibilities. This work is critical to understanding current adequacy and future possibilities for iLab to function as the system through which investigator tracking and support data is collected for analysis. This work also is critical to quality assurance for quarterly reporting processes and programmatic assessment more broadly.

To this end, TEC personnel began a two-phase study with the aim of more clearly understanding 1) how personnel with different roles currently use iLab and 2) the potential for the iLab tool within the context of WVCTSI. To date, we have conducted one focus group of seven iLab administrators and frequent users and four individual interviews. This data is being analyzed, and a second set of interviews is being scheduled.

**Specific Aim 2. Create and implement systematic set of tools and measurements to drive continuous quality improvement and demonstrate impact of community stakeholder participation and engagement.**

In Q1, a report describing findings from a baseline survey of WVPBRN members was disseminated internally. This work was accepted during Q1 for presentation at the American Evaluation Association meeting in a subsequent reporting period. Also, a collaboration survey was administered to support social network analysis and future reporting of connectivity across the WVPBRN.

**Specific Aim 3. Build focused research and evaluation demonstrating WVCTSI impacts on health outcomes in West Virginia.**

The Tracking and Evaluation Report for the 4<sup>th</sup> Quarter of Fiscal Year 2017-2018 was disseminated in Q1. TEC personnel supported refinement of the overall dashboard and drove development and refinement of partner dashboards for inclusion in quarterly reports. TEC also developed a social network visualization of connectivity among authors on linked publications. Additionally, a TEC core member contributed to writing a proposal and developing qualitative and quantitative measures for an NIH supplement designed with the following two specific aims: 1) describe community attitudes toward opioid use disorder and harm reduction services including syringe exchange, and 2) understand the multilevel syndemic factors that may contribute to development of opioid use disorder among young women for the purposes of informing future intervention studies.



### Tracking & Evaluation

#### Key Recommendations

- Identify next steps for utilization of iLab data to inform robust investigator tracking and support.
- Support continued refinement of partner dashboards.



### Marshall University

Marshall University, located in Huntington, WV in Cabell County, partners with the WVCTSI and is engaged in activities primarily related to research



and investigator development. The Joan C. Edwards School of Medicine at Marshall University is a community-based, Veterans Affairs-affiliated medical school dedicated to providing high quality medical education and postgraduate training programs to foster a skilled physician workforce to meet the unique healthcare needs of West Virginia and Central Appalachia. The Joan C. Edwards School of Medicine focuses on developing centers of excellence in clinical care, including primary care in rural underserved areas, focused and responsive programs of biomedical science graduate study, biomedical and clinical science research, academic scholarship, and public service outreach. Marshall University houses the WVCTSI's Associate Director, Dr. Gary Rankin.

For the 1<sup>st</sup> quarter of 2018-2019, Marshall reported 1 peer-reviewed publications and 2 external funding proposals submitted. Among the total 2,094 WVCTSI members, 29 are affiliated with Marshall University. Marshall has worked collaboratively with many WVCTSI cores in Q1, for instance Admin has provided proposal development to 5 Marshall members. Also, Marshall with PD core has a student who serves in both the research and marketing committee with Healthy Connections. This same student is also PI on a WVCTSI funded project titled "Using exome sequencing approach to enhance the treatment of pregnant women with opioid use disorder and their neonates". PD has also reported presentation collaboration that consisted of PD, Pilots, and MU. TRCL core reported that 92 biospecimen samples were used by MU, as well as 138 biospecimen samples collected. Additionally, two students from Marshall are INTRO students.

#### Marshall University

##### Key Recommendations

- Work to increase utilization of iLab.
- Continue efforts to increase WVCTSI membership.

**Charleston Area Medical Center (CAMC)**

CAMC activity in Q1 of Year 7 was similar to or in excess of activity for the entirety of Year 6, with the exception of external funding proposals and awards.



In the 1<sup>st</sup> quarter of 2018-2019, CAMC reported 1 linked publication, 1 presentation, and 36 WVCTSI members.

Connected to the CRDEB core, there were 12 biostatistics consultations, 6 journal clubs attended, 3 seminars/workshops delivered, 2 iLab users, and 12 REDCap users at CAMC.

Connected to the Professional Development core, CAMC reported 16 clinicians and staff members participating in WVCTSI sponsored research training programs and 7 workshops / courses / seminars / retreats.

Connected to the CEO core, CAMC reported participation in 5 community research projects and 4 collaborations with CTS projects outside of WVPBRN.

There was 1 pilot project ongoing at CAMC and 1 pilot project collaboratively funded by WVU and CAMC related to WVPBRN.

**Charleston Area Medical Center****Key Recommendations**

- Work with Administration Core to ensure membership list is accurate given that Admin reported 56 WVCTSI members at CAMC.
- Consider opportunities to increase external funding activity.
- Identify year 7 annual targets for all appropriate metrics.



### West Virginia School of Osteopathic Medicine (WVSOM)

WVSOM, located in Lewisburg, WV in Greenbrier County, partners with the WVCTSI and is engaged in activities related to research and community engagement. WVSOM focuses on educating students as lifelong learners in osteopathic medicine and complementary health related programs, supporting graduate medical education training, advancing scientific knowledge through academic, clinical, and basic science research, and promoting patient-centered, evidence-based medicine.



In the 1<sup>st</sup> quarter of 2018-2019, WVSOM reported 4 external funding awards, 2 Collaborative Pilot projects funded, and 10 presentations supported by WVCTSI. No early stage investigators were reported to have been accessing WVCTSI services and resources. Among the total 2,094 WVCTSI members, 72 were affiliated with WVSOM.

Of the affiliated WVSOM members, none were reported as receiving professional development services in Q1. However, several other activities were reported. Related to professional development, there were 2 opportunities for students to participate in clinical and translational research and 9 workshops / courses / seminars / retreats with WVSOM participants. There was 1 Current Alliance CTS collaboration; 5 research projects initiated; 2 ongoing Pilots projects; and 1 closeout meeting with Pilot Core Consultations. There were 8 REDCap users and 1 ongoing REDCap project affiliated with WVSOM.

#### WV School of Osteopathic Medicine

##### Key Recommendations

- Work with Administration core to ensure that external funding awards at WVSOM are appropriately reported through WVCTSI Admin.
- Work toward increasing awareness and utilization of WVCTSI core services by personnel at WVSOM, especially early stage and new investigators.
- Identify year 7 annual targets for all appropriate metrics.